Berlin, August 15, 2011 – Bayer HealthCare has agreed to support the World Health Organization (WHO) and the Stop TB Partnership in the fight against multidrug-resistant tuberculosis (MDR-TB) by making 620,000 tablets of the antibiotic moxifloxacin available to WHO. Through the Stop TB Partnership's Global Drug Facility, WHO will provide the antibiotics to China's national TB programme. “We have decided to make moxifloxacin available to provide quick support to those patients in need”, said Dr. Jörg Reinhardt, Chairman of the Board of Management of Bayer HealthCare. “We were happy to follow the request from WHO because we believe that this is the right step to address an increasing medical need in patients affected with this serious disease and for whom there are only very limited oral treatment options available.”
